Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Free Cash Flow (2021 - 2025)

Senti Biosciences has reported Free Cash Flow over the past 5 years, most recently at -$6.9 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$6.9 million for Q4 2025, up 49.13% from a year ago — trailing twelve months through Dec 2025 was -$43.6 million (down 5.35% YoY), and the annual figure for FY2025 was -$43.6 million, down 5.35%.
  • Free Cash Flow for Q4 2025 was -$6.9 million at Senti Biosciences, up from -$9.4 million in the prior quarter.
  • Over the last five years, Free Cash Flow for SNTI hit a ceiling of -$934675.0 in Q2 2021 and a floor of -$21.1 million in Q1 2023.
  • Median Free Cash Flow over the past 5 years was -$8.4 million (2024), compared with a mean of -$9.9 million.
  • Biggest five-year swings in Free Cash Flow: plummeted 722.32% in 2022 and later surged 56.21% in 2024.
  • Senti Biosciences' Free Cash Flow stood at -$4.5 million in 2021, then crashed by 118.28% to -$9.8 million in 2022, then increased by 28.06% to -$7.0 million in 2023, then plummeted by 91.73% to -$13.5 million in 2024, then surged by 49.13% to -$6.9 million in 2025.
  • The last three reported values for Free Cash Flow were -$6.9 million (Q4 2025), -$9.4 million (Q3 2025), and -$13.1 million (Q2 2025) per Business Quant data.